Evidence map›Paper›PMID 28382542›Full record

ArticlePsychopharmacology2017

KK-92A, a novel GABA

Xia Li, Emmanuel Sturchler, Katarzyna Kaczanowska, Michael Cameron, M G Finn, Patrick Griffin, Patricia McDonald, Athina Markou

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Nicotine addiction: More than just dopamine.Current opinion in neurobiology · 2023
    Review
  3. Delving into the reducing effects of the GABAAlcohol (Fayetteville, N.Y.) · 2023
    Article
  4. Article
  5. GABACurrent topics in behavioral neurosciences · 2022
    Review
  6. GABACurrent topics in behavioral neurosciences · 2022
    Article
  7. The Novel Positive Allosteric Modulator of the GABAFrontiers in cell and developmental biology · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xia LiDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.
Emmanuel SturchlerThe Scripps Research Institute, Jupiter, FL, USA.
Katarzyna KaczanowskaThe Scripps Research Institute, La Jolla, CA, USA.
Michael CameronThe Scripps Research Institute, Jupiter, FL, USA.
M G FinnThe Scripps Research Institute, La Jolla, CA, USA.
Patrick GriffinThe Scripps Research Institute, Jupiter, FL, USA.
Patricia McDonaldThe Scripps Research Institute, Jupiter, FL, USA. mcdonaph@scripps.edu.
Athina MarkouDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.

Funding

Funct character of GABA_B receptor modulators, drug metabolism, pharmacokineticsU19DA026838 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MARKOU, ATHINA · 2010 to 2014
$7.3M
NIDA NIH HHS U19 DA026838
6 · The paper itself

Abstract

rationaleGABA

objectivesThe present study was aimed at developing novel, selective, and potent GABA

resultsWe synthetized ~100 analogs of BHF177, a GABA

conclusionsThese results indicate that KK-92A is a selective GABA

Indexed as

CuesAllosteric RegulationAnimalsBehavior, AddictiveCHO CellsCricetinaeCricetulusDose-Response Relationship, DrugGABA-B Receptor AgonistsGABA ModulatorsHumansMaleMotivationNicotineRatsRats, WistarGABA-B Receptor AgonistsGABA ModulatorsNicotineReceptors, GABA-BAllosteric modulatorGABA receptorGPCRNicotineRelapseSelf-administration

Identifiers

PMID28382542

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.